1
|
Nisar M, Gondal HY, Cheema ZM, Yousaf S, Nadeem H. New azole-derived hemiaminal ethers as promising acetylcholinesterase inhibitors: synthesis, X-ray structures, in vitro and in silico studies. J Biomol Struct Dyn 2023; 41:15535-15548. [PMID: 37021341 DOI: 10.1080/07391102.2023.2190805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 03/05/2023] [Indexed: 04/07/2023]
Abstract
A new class of azole-derived hemiaminal ethers is designed as acetylcholinesterase (AChE) inhibitors. The synthesized compounds exhibited remarkable inhibitory activity against acetylcholine. Chiral hemiaminals (3d and 3i) based on (R)-menthoxymethyl group exhibit excellent inhibition with IC50 values of 0.983 ± 1.41 and 1.154 ± 0.89 µM. Similarly, butoxymethyl derivatives 3a, 3f and 3h, also showed promising inhibition comparable to the standard drug, Donepezil. In silico studies were performed to understand the mode of interactions with the target proteins, where menthoxymethyl azoles 3d and 3i demonstrated the highest docking scores. Molecular dynamics simulations displayed the stable ligand-protein complex of 3i with effective binding interactions. The bioavailability and pharmacokinetic parameterssupported the suitability of these small molecule inhibitors to develop cost-effective drug leads for Alzheimer's disease (AD). MTT assay substantiated the non-cytotoxic nature of the compounds. The synthesized compounds are extensively characterized by 1H NMR, 13C NMR and mass spectral data and SC-XRD.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Muhammad Nisar
- Institute of Chemistry, University of Sargodha, Sargodha, Pakistan
| | | | | | - Sammer Yousaf
- HEJ Research Institute of Chemistry, ICCBS, University of Karachi, Pakistan
| | - Humaira Nadeem
- Department of Pharmaceutical Chemistry, Riphah International University, Islamabad, Pakistan
| |
Collapse
|
3
|
Al-Otaibi JS, Mary YS, Mary YS, Thirunavukkarasu M, Trivedi R, Chakraborty B. Conformational, Reactivity Analysis, Wavefunction-Based Properties, Molecular Docking and Simulations of a Benzamide Derivative with Potential Antitumor Activity-DFT and MD Simulations. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2039229] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Jamelah S. Al-Otaibi
- Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | | | | | - M. Thirunavukkarasu
- Department of Physics, Indo-American College, Cheyyar, Tamil Nadu, India
- Department of Physics, Thiru A. Govindasamy Govt. Arts College, Tindivanam, Tamil Nadu, India
| | - Ravi Trivedi
- Department of Physics, Indian Institute of Technology, Mumbai, India
| | - Brahmananda Chakraborty
- High Pressure and Synchrotron Radiation Physics Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
6
|
Hayashi Y, Kawakubo-Yasukochi T, Mizokami A, Hazekawa M, Yakura T, Naito M, Takeuchi H, Nakamura S, Hirata M. Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth. J Cancer 2017; 8:2478-2486. [PMID: 28900485 PMCID: PMC5595077 DOI: 10.7150/jca.18648] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Accepted: 06/04/2017] [Indexed: 12/20/2022] Open
Abstract
Because of the poor response to chemotherapy and radiation therapy, new treatment approaches by immune-based therapy involving activated T cells are required for melanoma. We previously reported that the uncarboxylated form of osteocalcin (GluOC), derived from osteoblasts, potentially suppresses human prostate cancer cell proliferation by direct suppression of cell growth. However, the mechanisms in vivo have not been elucidated. In this study, we found that GluOC suppressed tumor growth of B16 mouse melanoma transplants in C57Bl/6N wild-type mice. Our data demonstrated that GluOC suppressed cell growth by downregulating phosphorylation levels of receptor tyrosine kinases and inducing apoptosis in vitro. Additionally, stimulation of primary mouse splenocytes with concanavalin A, a polyclonal T-cell mitogen, in the presence of GluOC increased T cell proliferation and their interferon-γ production. Taken together, we demonstrate that GluOC exerts multiple antitumor effects not only in vitro, but also in vivo through cellular immunostimulatory effects against B16 mouse melanoma cells.
Collapse
Affiliation(s)
- Yoshikazu Hayashi
- Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.,Section of Oral and Maxillofacial Oncology, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | - Tomoyo Kawakubo-Yasukochi
- Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.,Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, Fukuoka 814-0180, Japan
| | - Akiko Mizokami
- Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.,OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | - Mai Hazekawa
- Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, Fukuoka 814-0180, Japan
| | - Tomiko Yakura
- Department of Anatomy, Aichi Medical University, Aichi 480-1195, Japan
| | - Munekazu Naito
- Department of Anatomy, Aichi Medical University, Aichi 480-1195, Japan
| | - Hiroshi Takeuchi
- Division of Applied Pharmacology, Kyushu Dental University, Kitakyushu 803-8580, Japan
| | - Seiji Nakamura
- Section of Oral and Maxillofacial Oncology, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | - Masato Hirata
- Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.,Fukuoka Dental College, Fukuoka 814-0193, Japan
| |
Collapse
|
8
|
Borst DL, Arruda LS, MacLean E, Pithavala YK, Morgado JE. Common questions regarding clinical use of axitinib in advanced renal cell carcinoma. Am J Health Syst Pharm 2015; 71:1092-6. [PMID: 24939498 DOI: 10.2146/ajhp130581] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE An overview of the responses to some of the most frequently asked questions regarding axitinib administration and dosage modifications used in clinical practice are presented. SUMMARY Axitinib was approved for second-line treatment of advanced renal cell carcinoma by the Food and Drug Administration on January 27, 2012. Inquiries received over the first six months after the approval date were reviewed. A large number of questions were related to administration of axitinib in different patient populations or in patients with various comorbidities, such as its (1) use in patients unable to swallow oral medication or administration of axitinib via a nasogastric tube, (2) use in patients with renal or hepatic impairment, (3) central nervous system penetration and use in patients with brain metastases, (4) drug interactions, particularly with anticoagulants, and (5) dosage modifications. Responses to these inquiries were provided based on the published literature or from data on file from the manufacturer. The dosage of axitinib can be adjusted for use in patients with hepatic impairment or in patients who cannot otherwise tolerate the usual regimen. Patients taking concomitant warfarin can also take axitinib, and patients who cannot swallow oral medications can receive a liquid formulation of the drug, though its efficacy and comparability to the tablet formulation has not been tested. CONCLUSION Based on the published literature and company data on file, the axitinib dosage may be modified to accommodate patients with renal or hepatic impairment, who cannot swallow oral medication, are receiving concomitant warfarin, or who cannot otherwise tolerate the standard dosage regimen. For patients who cannot swallow, an oral suspension can be prepared because crushing axitinib is not recommended.
Collapse
Affiliation(s)
- Diane L Borst
- Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT.
| | - Lillian S Arruda
- Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT
| | - Elizabeth MacLean
- Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT
| | - Yazdi K Pithavala
- Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT
| | - James E Morgado
- Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT
| |
Collapse
|
9
|
Qi WX, He AN, Shen Z, Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2014; 76:348-57. [PMID: 23617405 DOI: 10.1111/bcp.12149] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2013] [Accepted: 04/12/2013] [Indexed: 01/13/2023] Open
Abstract
AIMS To investigate the overall incidence and risk of hypertension in cancer patients who receive axitinib and compare the differences in incidences between axitinib and the other four approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). METHODS Several databases were searched, including Pubmed, Embase and Cochrane databases. Eligible studies were phase II and III prospective clinical trials of patients with cancer assigned axitinib at a starting dose of 5 mg orally twice daily with data on hypertension available. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed or random effects models depending on the heterogeneity of the included trials. RESULTS A total of 1908 patients from 10 clinical trials were included. The overall incidences of all grade and high grade hypertension in cancer patients were 40.1% (95% CI 30.9, 50.2%) and 13.1% (95% CI 6.7, 24%). The use of axitinib was associated with significantly increased risk of all grade (RR 3.00, 95% CI 1.29, 6.97, P = 0.011) and high grade hypertension (RR 1.71, 95% CI 1.21, 2.43, P = 0.003). The risk of axitinib associated all grade and high grade hypertension in renal cell carcinoma (RCC) was significantly higher than that in non-RCC. Additionally, the risk of hypertension with axitinib was substantially higher than other approved VEGFR-TKIs, while the risk of all grade hypertension with axitinib was similar to pazopanib (RR 1.05; 95% CI 0.95-, 1.17, P = 0.34). CONCLUSIONS While sharing a similar spectrum of target receptors with other VEGFR-TKIs, axitinib is associated with an unexpectedly high risk of developing hypertension. Close monitoring and appropriate management for hypertension are recommended during the treatment.
Collapse
Affiliation(s)
- Wei-Xiang Qi
- Department of Oncology, The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, 200233, China
| | | | | | | |
Collapse
|